- 期刊
- OpenAccess
PPI-clarithromycin-metronidazole三聯療法一線根除幽門螺桿菌的回顧性分析
A retrospective study on the eradication rate of PPI-clarithromycin-metronidazole triple therapy as first-line treatment for H. pylori infection
摘要
目的：因抗生素耐藥比例增加，PPI-clarithromycin-metronidazole三聯療法在本澳一線治療幽門螺桿菌的根除率需進一步研究。方法：回顧性分析2012年7月1日～2017年6月3日本院含metronidazole三聯療法一線根治幽門螺桿菌並複查的成人連續患者，分別紀錄其一般情況、藥敏情況、根除方案及根除療效。結果：共32例患者納入研究，16例根除成功，16例根除失敗，總體根除率為50.0%。不同性別、年齡、治療年份、有無青霉素過敏、不同metronidazole劑量或治療療程亞組間差異無統計學意義。結論：本組患者中含metronidazole的三聯方案根除率僅為50%，於本澳地區根除率低。
並列摘要
Objective: To assess the eradication rate of PPI-clarithromycin-metronidazole triple therapy as first-line treatment for H.pylori infection in Macao. Methods: H.pylori infected patients who received PPI-clarithromycin-metronidazole triple therapyand confirmed the eradiation between July, 01, 2012 and June, 30, 2017 in Kiang Wu Hospital were recorded. Their clinical characters were analyzed. Results: A total of 32 patients were recruited. H.pylori eradication was achieved in 16 of 32 (50.0%) patients. No significant differences were found between different gender, age, time, penicillin allergy history, metronidazole dosage or treatment duration. Conclusion: PPI-clarithromycin-metronidazole triple therapy showed low eradication rate.